Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visudyne, triamcinolone acetonide, and Lucentis in wet age-related macular degeneration
ChiCTR-TNC-08000175Phase 2Completed
- Sponsor
- University of Udine
- Start
- Sep 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ranibizumab, triamcinolone acetonide and verteporfin in age-related macular degeneration (AMD) and Subretinal neovascularization (3 arms), sponsored by University of Udine. Primary endpoints: Number of retreatments and Visual acuity. Started Sep 2007; status: completed.
02
Drugs
ranibizumabtriamcinolone acetonideverteporfin
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on ChiCTR-TNC-08000175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-08000175.